Alto Neuroscience Statistics
Total Valuation
ANRO has a market cap or net worth of $1.02 billion. The enterprise value is $716.28 million.
Important Dates
The last earnings date was Tuesday, November 10, 2026, after market close.
| Earnings Date | Nov 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ANRO has 40.11 million shares outstanding. The number of shares has increased by 49.21% in one year.
| Current Share Class | 40.11M |
| Shares Outstanding | 40.11M |
| Shares Change (YoY) | +49.21% |
| Shares Change (QoQ) | +8.68% |
| Owned by Insiders (%) | 2.45% |
| Owned by Institutions (%) | 81.04% |
| Float | 30.46M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.42 |
| P/TBV Ratio | 3.43 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 18.12, with a Debt / Equity ratio of 0.06.
| Current Ratio | 18.12 |
| Quick Ratio | 17.90 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -48.48 |
Financial Efficiency
Return on equity (ROE) is -46.65% and return on invested capital (ROIC) is -27.71%.
| Return on Equity (ROE) | -46.65% |
| Return on Assets (ROA) | -26.54% |
| Return on Invested Capital (ROIC) | -27.71% |
| Return on Capital Employed (ROCE) | -32.57% |
| Weighted Average Cost of Capital (WACC) | 12.14% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.40M |
| Employee Count | 68 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +63.26% in the last 52 weeks. The beta is 1.45, so ANRO's price volatility has been higher than the market average.
| Beta (5Y) | 1.45 |
| 52-Week Price Change | +63.26% |
| 50-Day Moving Average | 25.58 |
| 200-Day Moving Average | 25.00 |
| Relative Strength Index (RSI) | 48.54 |
| Average Volume (20 Days) | 624,050 |
Short Selling Information
The latest short interest is 5.68 million, so 14.17% of the outstanding shares have been sold short.
| Short Interest | 5.68M |
| Short Previous Month | 4.66M |
| Short % of Shares Out | 14.17% |
| Short % of Float | 18.65% |
| Short Ratio (days to cover) | 9.03 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -100.55M |
| Pretax Income | -95.18M |
| Net Income | -95.18M |
| EBITDA | -99.84M |
| EBIT | -100.55M |
| Earnings Per Share (EPS) | -$2.36 |
Full Income Statement Balance Sheet
The company has $319.34 million in cash and $18.02 million in debt, with a net cash position of $301.32 million or $7.51 per share.
| Cash & Cash Equivalents | 319.34M |
| Total Debt | 18.02M |
| Net Cash | 301.32M |
| Net Cash Per Share | $7.51 |
| Equity (Book Value) | 296.53M |
| Book Value Per Share | 7.42 |
| Working Capital | 305.36M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$79.12 million and capital expenditures -$556,000, giving a free cash flow of -$79.68 million.
| Operating Cash Flow | -79.12M |
| Capital Expenditures | -556,000 |
| Depreciation & Amortization | 706,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -79.68M |
| FCF Per Share | -$1.99 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ANRO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -49.21% |
| Shareholder Yield | -49.21% |
| Earnings Yield | -9.31% |
| FCF Yield | -7.83% |
Analyst Forecast
The average price target for ANRO is $38.67, which is 52.42% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $38.67 |
| Price Target Difference | 52.42% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 3 |